Merit CE marks haemostasis valve:
This article was originally published in Clinica
Merit Medical Systems has CE-marked its new MBA haemostasis valve. The valve reduces the amount of blood which escapes during the use of interventional devices such as angioplasty balloons and stent catheters, says the South Jordan, Utah-based company. The MBA has a larger inner lumen than other haemostatic valves and can accommodate catheters up to 9 French, claims Merit.
You may also be interested in...
Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.